-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Climb Bio, Maintains $20 Price Target

Benzinga·08/19/2026 12:46:04
Listen to the news
Wedbush analyst Laura Chico reiterates Climb Bio (NASDAQ:CLYM) with a Outperform and maintains $20 price target.